Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 8 Results

Title
Intervention Indication Therapeutic Area Year Actions
Daratumumab in addition to bortezomib, lenalidomide and dexamethasone for multiple myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Daratumumab in addition to Bortezomib, Thalidomide and Dexamethasone for newly diagnosed Multiple Myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Thalidomide (Taldo) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Daratumumab in addition to cyclophosphamide, bortezomib and dexamethasone for newly diagnosed systemic amyloid light-chain amyloidosis Bortezomib (Velcade; bortezomib mannitol boronic ester) , Cyclophosphamide (Procytox; cyclophosphamide monohydrate) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Amyloidosis Endocrine Nutritional and Metabolic Disorders 2020 View  |  Download
Daratumumab in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Melphalan , Prednisone (Decadron; Lodotra) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications